President Trump’s plans to cut healthcare costs include putting pressure on other countries, via trade agreements, to pay more for pharmaceuticals. It isn’t clear what form this will take – other than encouraging countries to move away from single-buyer models – and hasn’t so far been included in either the NAFTA or KORUS discussions. The relative movement of international trade values of pharmaceuticals can give a sense of relative price movements. U.S. import drug prices per unit are down 29% from their peak and by 32% since 2010 on a trailing 12 month basis, suggesting overseas prices...